:: Library Catalog

Cover Image

Saved in:

Bibliographic Details
Main Authors:	Shuai Xia, Zhiying He, Xiaoning Wu, Zhongjie Hu, Chunqing Zhang, Yanqin Hao, Yongfeng Yang, Yan Huang, Wei Rao, Xiaoqian Xu, Xinyu Zhao, Jialing Zhou, Yameng Sun, Shuyan Chen, Luqi Tang, Xiaojuan Ou, Xinyan Zhao, Jidong Jia, Bingqiong Wang, Hong You
Format:	Artículo Open Access
Published:	Wiley 2025
Subjects:	Alimentary Pharmacology & Therapeutics
Online Access:	https://onlinelibrary.wiley.com/doi/10.1111/apt.70430
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Editorial: Caught in the Middle—Exploring the Grey Zone Between Decompensated and Recompensated HBV ‐Related Cirrhosis. Authors' Reply
by: Bingqiong Wang, et al.
Published: (2025)

Editorial: Caught in the Middle—Exploring the Grey Zone Between Decompensated and Recompensated HBV ‐Related Cirrhosis
by: Stephanie Tsai, et al.
Published: (2025)

Lymphocyte‐to‐Monocyte Ratio as a Predictor of Recompensation in Patients With Decompensated Primary Biliary Cholangitis
by: Huiying Lin, et al.
Published: (2025)

Editorial: Diabetes Management in Cirrhosis—The Window of Opportunity Before Decompensation
by: Thanawin Pramotedham, et al.
Published: (2026)

Editorial: Redefining Decompensation in Cirrhosis—More Than an Academic Playground? Authors' Reply
by: Lucie Simonis, et al.
Published: (2025)

Editorial: Diabetes Management in Cirrhosis—The Window of Opportunity Before Decompensation. Authors' Reply
by: Mary Yue Wang, et al.
Published: (2026)

Patient Plasma‐Induced Neutrophil Dysfunction Is Associated With Infection Risk and Mortality in Patients With Acute Decompensation of Cirrhosis
by: Supachaya Sriphoosanaphan, et al.
Published: (2025)

Letter: Optimising Prevention of Adverse Events and Antiviral Prophylaxis for HBV ‐Infected HCC Patients Undergoing Immunotherapy
by: Jialing Wang, et al.
Published: (2025)

Editorial: ABID‐LSM–A Promising Model for Predicting Decompensation Risk in MASLD Cirrhosis
by: Eduardo Vilar‐Gomez, et al.
Published: (2025)

Refining Prognosis in Cirrhosis Patients With Ascites: Impact of Acute vs. Non‐Acute Decompensation
by: Lucie Simonis, et al.
Published: (2025)

Predicting Hepatic Decompensation in Patients With Metabolic Dysfunction Associated Steatotic Liver Disease‐Related Cirrhosis: The ABID‐LSM Model
by: Luis Calzadilla Bertot, et al.
Published: (2025)

Serum Villin‐1—A Novel Marker of Gut Barrier Damage in Acutely Decompensated Cirrhosis: A Cohort Study and Validation
by: David Tornai, et al.
Published: (2025)

Editorial: Recompensation in PBC is good. But is it good enough? Authors' reply
by: Benedikt Silvester Hofer, et al.
Published: (2024)

Letter: Attempted Validation of Villin‐1 as a Gut Barrier Marker in Decompensated Cirrhosis—Potential Confounding by Tubular Injury and Aetiology. Authors' Reply
by: David Tornai, et al.
Published: (2026)

Letter: Trajectories of Hepatic Function Markers Enable Early Prediction of Hepatic Recompensation
by: Benedikt Silvester Hofer, et al.
Published: (2026)

Editorial: HBV Integration: A Possible Key Driver in the Course of Patients With Chronic HBV Infection Under Viral Suppression
by: Hidenori Toyoda
Published: (2025)

Positivity of high‐sensitivity HBsAg test, not previous HBV infection, indicates poor prognosis in patients with non‐HBV‐related HCC
by: Naohiro Yasuura, et al.
Published: (2024)

Editorial: HBV Integration—A Possible Key Driver on the Course of Patients With Chronic HBV Infection Under Viral Suppression. Authors' Reply
by: Qin Ning, et al.
Published: (2025)

Differential Characteristics and Survival Outcomes of Patients With Cirrhosis According to Underlying Liver Aetiology
by: Yu Shi, et al.
Published: (2025)

Barriers to Medical Care Are Frequently Reported by Patients With Cirrhosis
by: William Chai, et al.
Published: (2025)

Editorial: Beyond DNA Suppression: HBV RNA as a Predictor of Hepatocarcinogenesis
by: Toshifumi Tada
Published: (2025)

Editorial: Trajectory of soluble programmed cell death protein‐1 and ligand‐1 in HBV‐infected individuals treated with pegylated interferon—implications for stopping rules and the HBV cure programme
by: James Lok
Published: (2024)

Editorial: Timely Follow‐Up in Cirrhosis: How Does It Work?
by: Nina Kimer, et al.
Published: (2024)

Letter: The Unresolved Issue of NSBB Confounding in Statin Research for Cirrhosis
by: Deliang Huang, et al.
Published: (2026)

Editorial: Assessing the Prognosis of Patients With HBV and ACLF—Comorbidities Matter. Authors' Reply
by: Jiong Yu, et al.
Published: (2024)

Editorial: Immune Checkpoint Inhibitors and HBV Reactivation in Liver Cancer—Reassurance With Vigilance
by: Romeo Kuo‐Cheng Wu, et al.
Published: (2025)

Editorial: Trajectory of soluble programmed cell death protein‐1 and ligand‐1 in HBV‐infected individuals treated with pegylated interferon—Implications for stopping rules and the HBV cure programme. Authors' reply
by: Chan Xie
Published: (2024)

Editorial: Statin Therapy in Cirrhosis: More Than Just Lipid‐Lowering
by: Emily Stephenson, et al.
Published: (2026)

Amino Acid Imbalance Is an Independent Factor for Mortality in Patients With Liver Cirrhosis
by: Yuki Utakata, et al.
Published: (2026)

Editorial: Linking Patients With Cirrhosis to Clinical Care—The Hurdles and Way Forward
by: Jimmy Che‐To Lai, et al.
Published: (2026)

Letter on ‘Association Between Viral Replication Activity and Postoperative Recurrence of HBV‐Related Hepatocellular Carcinoma’
by: Dong Hyun Kim, et al.
Published: (2025)

Editorial: Immune Checkpoint Inhibitors and HBV Reactivation in Liver Cancer—Reassurance With Vigilance. Authors' Reply
by: Terry Cheuk‐Fung Yip, et al.
Published: (2025)

Letter: Using Anti‐ HBs Titres to Tailor HBV Reactivation Monitoring in Patients With Solid Tumours
by: Tsutomu Nishida, et al.
Published: (2026)

Letter: Association Between Viral Replication Activity and Postoperative Recurrence of HBV‐Related Hepatocellular Carcinoma
by: Sifu Yang
Published: (2025)

Letter: Timely Follow‐Up in Cirrhosis—A Key Public Health Intervention
by: Mo‐Yao Tan, et al.
Published: (2024)

Editorial: Polypharmacy in MASLD—An Overlooked Epidemic Disproportionately Affecting Women and Patients With Cirrhosis
by: Mary Yue Wang, et al.
Published: (2025)

Letter: Amino Acid Imbalance Is an Independent Factor for Mortality in Patients With Liver Cirrhosis
by: Zhanbo Qu
Published: (2026)

Editorial: How to Interpret Clinical Impact of Viral Replication Activity for Postoperative Recurrence of HBV‐Related HCC
by: Beom Kyung Kim
Published: (2025)

Letter on: ‘Impact of Frailty on the Prognosis of Patients With Liver Cirrhosis Undergoing Insertion of a TIPS ’
by: Sai Kiran Kuchana, et al.
Published: (2026)

Letter: Amino Acid Imbalance and Mortality in Cirrhosis—Interpretation and Methodological Considerations. Authors' Reply
by: Yuki Utakata, et al.
Published: (2026)